LifeMD (NASDAQ:LFMD) Stock Rating Reaffirmed by Cantor Fitzgerald

LifeMD (NASDAQ:LFMD)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 205.50% from the company’s previous close.

A number of other equities analysts also recently issued reports on the stock. KeyCorp dropped their price objective on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. B. Riley assumed coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.00.

LifeMD Trading Down 7.0 %

LFMD opened at $4.91 on Friday. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The stock’s fifty day moving average is $5.70 and its two-hundred day moving average is $7.82. The company has a market capitalization of $205.03 million, a P/E ratio of -6.64 and a beta of 1.19. LifeMD has a 52 week low of $4.05 and a 52 week high of $12.88.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to analysts’ expectations of $48.47 million. During the same quarter in the prior year, the company posted ($0.23) EPS. Analysts forecast that LifeMD will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On LifeMD

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in LifeMD in the second quarter worth about $31,000. Los Angeles Capital Management LLC purchased a new position in shares of LifeMD in the 2nd quarter valued at approximately $88,000. EntryPoint Capital LLC acquired a new stake in LifeMD in the 1st quarter worth approximately $89,000. The Manufacturers Life Insurance Company purchased a new stake in LifeMD during the 2nd quarter worth approximately $93,000. Finally, XTX Topco Ltd acquired a new position in LifeMD during the 2nd quarter valued at approximately $94,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.